214 related articles for article (PubMed ID: 23998430)
1. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors.
Gulbahce HE; Sweeney C; Surowiecka M; Knapp D; Varghese L; Blair CK
Hum Pathol; 2013 Nov; 44(11):2427-31. PubMed ID: 23998430
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
3. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy.
Goyal S; Parikh RR; Green C; Schiff D; Moran MS; Yang Q; Haffty BG
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):679-84. PubMed ID: 19464815
[TBL] [Abstract][Full Text] [Related]
6. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance.
Gonzalez RS; Wang J; Kraus T; Sullivan H; Adams AL; Cohen C
Hum Pathol; 2013 Jun; 44(6):1065-70. PubMed ID: 23266442
[TBL] [Abstract][Full Text] [Related]
7. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
8. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.
Kok M; Koornstra RH; Mook S; Hauptmann M; Fles R; Jansen MP; Berns EM; Linn SC; Van 't Veer LJ
Breast; 2012 Dec; 21(6):769-78. PubMed ID: 22738860
[TBL] [Abstract][Full Text] [Related]
9. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.
Voduc D; Cheang M; Nielsen T
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):365-73. PubMed ID: 18268121
[TBL] [Abstract][Full Text] [Related]
10. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy.
Takei H; Horiguchi J; Maemura M; Koibuchi Y; Oyama T; Yokoe T; Iino Y; Morishita Y
Oncol Rep; 2002; 9(2):375-8. PubMed ID: 11836611
[TBL] [Abstract][Full Text] [Related]
12. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy in luminal breast cancers.
Lim E; Winer EP
Breast; 2011 Oct; 20 Suppl 3():S128-31. PubMed ID: 22015279
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
16. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
17. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
18. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
Stendahl M; Rydén L; Nordenskjöld B; Jönsson PE; Landberg G; Jirström K
Clin Cancer Res; 2006 Aug; 12(15):4614-8. PubMed ID: 16899609
[TBL] [Abstract][Full Text] [Related]
19. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
20. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
